This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
KAEL Co. Ltd.
Drug Names(s): EP HIV-1090
Description: The EP HIV-1090 vaccine is composed of 21 CTL epitopes, which were selected from conserved regions of multiple HIV proteins using EIS proprietary technology. The vaccine candidate is delivered as DNA combined with PVP, a polymer shown to increase the potency of DNA vaccines in animal studies. In addition, the vaccine includes PADRE universal helper T cell epitope, which is designed to enhance the magnitude and duration of CTL response.
Deal Structure: EP-1043 was acquired by Pharmexa from IDM Pharma in late 2005.
In April 2009, VaxOnco (a subdidiary of the Korean company KAEL) acquired Pharmexa-Epimmune (Pharmexa) by the purchase of all outstanding shares from Pharmexa A/S for 440,000. VaxOnco will thus assume all rights and responsibilities relating to the Pharmexa-Epimmune patent portfolio.
Additional information available to subscribers only: